Fred L. Elfman, Ph.D.

**** ****** ****** #* **********, CA 94010650-***-**** ac3hzk@r.postjobfree.com

Senior Research Scientist

Cell Biology Drug Discovery Target Validation

Highly experienced, multi-published Senior Scientist with proven track record directing complex development projects with specialization in cell and molecular biology. In-depth understanding of corporate/academic research goals, capable of anticipating the technological and resource needs to meet those goals. Collaborates efficiently with internal and external stakeholders to translate investigative studies into unique diagnostics and therapeutics. Works well independently, or as team member, in diverse environments.

Areas of Expertise:

Strategic/Analytical Thinker

Ensure Regulatory Compliance

Experimental Design including Oncology Models

Project Management

In Vivo/Vitro Experiments including Bioluminescence Rodent Cancer Models

Vendor Management

Plan/Design/Execute Clinical/Non-Clinical Trials including Small Molecules

Author Study Reports and Standard Operating Procedures

Technical Expertise

CELL BIOLOGY:Cell cultures with established lines, primary epithelial cell cultures and iPSC-derived neuron differentiations. Stromal/epithelial co-cultures and organogenesis. Investigative Procedures: Flow Cytometry, Phospho-flowAnalysis, In Vivo Imagining including digital morphometrics. In Vitro Mouse T-Cell co-cultures with multiple tumor types.

MOLECULAR BIOLOGY:PCR, qPCR,Plasmid transfections (liposome, calcium phosphate)/selection,

Lentiviral, BacMam transductions/selection,In situ hybridizations.

PROTEIN BIOCHEMISTRY:Western Blots, Micro-plate Assays, including ELISA, Affinity and Ion exchange chromatography.

MICROSCOPY/TISSUE SECTION BIOLOGY:Confocal (Core facility manager), Immunocytochemistry, Proximity ligand assays, Immunohistochemistry, including cryo/embedded tissue sectioning, staining optimization, and processing expertise. Xenograft tumor models including subcutaneous, renal capsule and other sites. Rodent in vivo models, including surgery, necropsy, and analysis.

Professional Experience

ACHELOIS PHARMA, Redwood City, CA. July 2017 - Current

Research Assistant

In Vitro Mouse T-Cell co-cultures with multiple tumor types.

Cell Cultures of Mouse T-Cells and multiple tumor types

Flow Cytometry Analysis of Mouse T-Cell/Tumor Co-Cultures

ASTRAZENICA-MEDIMMUNE (FSO Contractor), Mountain View, CA March 2017- July 2017

Cell Culture Specialist, Laboratory Support Group

Designed and began implementation of Mycoplasma and Cellular Identity Quality Maintenance Program.

Initiated Standard Operating Procedures Write-up.

Initiated Cell Culture Laboratory Staff Quality and Consistency Program including implementation of

.Novel Study-Specific Cellular Functional Standards.

EMD-MILLIPORESIGMA, Hayward, CA Sept. 2016 - Jan. 2017

Research Scientist II, Applications Laboratory

Designed and conducted novel Flow Cytometry-based assay to diagnose Glucose-6-Phosphate dehydrogenase

mutations in Malaria patients in the Third Word.

Analysis of novel Flow Cytometry assay data.

Assisted the development of novel staining methods of whole blood on behalf of improved Malaria diagnosis.

Assisted in testing of the company’s commercially available software products.

THE PARKINSON’S INSTITUTE AND CLINICAL CENTER, Sunnyvale, CA August 2011– February 2016

Examined, expanded, characterized, and banked large numbers of Neural Stem Cells taken from iPSCs of Parkinson’s patients diagnosed with monogenic forms of disease, organizing these cell stocks for future use.

Investigated demarcations and long-term culture of dopaminergic neurons from iPSC-derived Neural Stem Cells.

Adapted and optimized delineated procedures for 96-well format screening. Optimized substratum well-coating methods enabling improved Microelectrode Array analysis of differentiated dopaminergic neurons.

Developed novel freeze/thaw protocols for partially differentiated neuron cultures that optimized cost and time usage.

Optimized novel high-throughput analysis of electrophysiological/biochemical/morphological data innormal, mutant, & corrected dopaminergic neuron cultures, specifically:

oMicroelectrode Array analysis assays of spontaneous action potentials in cultured neurons.

oImmunocytochemistry for neuronal differentiation markers and autophagy induction.

oPlate reader assays measuring cellular proliferation, apoptosis, autophagy, and neurogenesis.

STANFORD UNIVERSITY SCHOOL OF MEDICINE, Stanford, CA August 2007– August 2011

DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY

Research Scientist, Nolan Laboratory, Baxter Laboratory for Stem Cell Biology

Lab Instructor, Group Co-Leader (2 years), Nolan Laboratory Phospho-Flow Course (2008-2010)

Designed, planned and led Flow Cytometry-based trials studying communication by phosphoprotein cascades in particular, adaptation of Phospho-flow analysis methods to study adherent cells:

oHuman cancer cell lines: breast, prostate, colon, lung, and brain.

oEpithelial cell/fibroblast co-cultures studying paracrine regulation of TGF -1 and EGF signaling.

oHuman endothelial cell primary cultures studying signaling defects in Pulmonary Hypertension patients.

oHSV-1-infected embryonic fibroblasts to access combinatorial drug efficacy,

(In collaboration with the Center for Cell Control, UCLA).

Trained staff and visiting colleagues in methods used above.

Created website covering “Analysis of Signaling Pathways in Innate Immunity Using Fluorescent Cell Bar-coding.”

GENENTECH, INC., South San Francisco, CA August 2004–February 2006

Research Associate, In Vivo Imaging Laboratory, Biomedical Imaging Group

Used CCD camera to conduct bioluminescence imaging of cancer models.

Utilized lab-developed software to analyze metastasis to evaluate experimental drugs, oversaw necropsy procedures.

Instructed client research laboratories in usage of bioluminescence imaging system software designed to produce, calculate, analyze, present and disseminate tumor growth data in rodent in vitro cancer models.

Procured supplies and ensured corporate and governmental bio-safety and radioactivity compliance.

Designed ELISA and paired luminometer/CCD camera bioassay methods.

Established multiple-lab standardization and quality control systems for cancer cell lines.

Additional Professional Experience includes Postgraduate Research at Proctor Foundation and Department of Anatomy, University of California; Postdoctoral Fellow at Cancer Institute, University of California; and

Staff Research Associate at Department of Medicine, University of California

Education

Ph.D., Anatomy, University of California, San Francisco, CA

(Laboratory of Gerald R. Cunha, Ph.D.)

Bachelor of Science, Zoology, University of Wisconsin, Madison, WI

Publications

1.Elfman, F. L., and Nichols, R. J. (Manuscript in preparation)

Increased resting action potentials in iPSC-derived cultured dopaminergic neurons with G2019S mutations and genetic deletions of LRRK2.

2.Margolis, T. P., Elfman, F. L., Leib, D., Pakpour, N., Apakupakul, K., Imai, Y., and Voytek, C. (2007).

Spontaneous reactivation of Herpes Simplex virus type 1 in latently infected murine sensory ganglia. Journal of Virology, October 2007, 110**-*****, Vol. 81, No. 20. http://jvi.asm.org/cgi/content/full/81/20/11069

3.Elfman, F., Bok, R., Conn, M., Shuman, M., and Cunha, G. (2001).

Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate. Differentiation 69, 108-120.

http://www.blackwell-synergy.com/doi/abs/10.1046/j.1432-0436.2001.690205.x

4.Evans, C. P., Elfman, F., Parangi, S., Conn, M., Cunha, G., and Shuman, M. A. (1997).

Inhibition of prostate cancer neovascularization and growth by urokinase plasminogen activator receptor blockade. Cancer Res 57, 3594-9.

5.Evans, C. P., Elfman, F., Cunha, G., and Shuman, M. (1997).

Decreased prostate cancer cell migration by inhibition of the insulin-like growth factor II/Mannose-6-Phosphate receptor.

Urologic Oncology, Vol. 3, Issue 5-6, 166-170.

6.Sutherland, R. S., Baskin, L. S., Elfman, F., Hayward, S. W., and Cunha, G. R. (1997).

The role of type IV collagenases in rat bladder development and obstruction. Pediatr Res 41, 430-4.

7.Lim, M., Elfman, F., Dohrman, A., Cunha, G., and Basbaum, C. (1995).

Upregulation of the 72-kDa type IV collagenase in epithelial and stromal cells during rat tracheal gland morphogenesis. Dev Biol 171, 521-30.

8.Shima, H., Tsuji, M., Elfman, F., and Cunha, G. R. (1995).

Development of male urogenital epithelia elicited by soluble mesenchymal. J Androl 16, 233-41.

9.Arrick, B. A., Lopez, A. R., Elfman, F., Ebner, R., Damsky, C. H., and Derynck, R. (1992).

Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol 118, 715-26.

10.Demeure, M. J., Damsky, C. H., Elfman, F., Goretzki, P. E., Wong, M. G., and Clark, O. H. (1992).

Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases. World J Surg 16, 770-6.

11.Perez, H. D., Kelly, E., Elfman, F., Armitage, G., and Winkler, J. (1991).

Defective polymorphonuclear leukocyte formyl peptide receptor(s) in juvenile periodontitis. J Clin Invest 87, 971-6.

12.Lobo, E., Elfman, F., Kelly, E., and Perez, H. D. (1990).

Effect of phorbol myristate acetate on processing of formyl peptide receptors by human neutrophils. Biochim Biophys Acta 1055, 193-6.

13.Perez, H. D., Elfman, F., Marder, S., Lobo, E., and Ives, H. E. (1989).

Formyl peptide-induced chemotaxis of human polymorphonuclear leukocytes does not require either marked changes in cytosolic calcium or specific granule discharge. Role of formyl peptide receptor reexpression (or recycling). J Clin Invest 83, 1963-70.

14.Kurrasch, R., Elfman, F., and Perez, H. D. (1989).

Polymorphonuclear leukocytes cap a derivative of wheat germ agglutinin upon stimulation with formyl peptide and C5a but not leukotriene B4. J Immunol 143, 1969-73.

15.Perez, H. D., Kelly, E., Chenoweth, D., and Elfman, F. (1988).

Identification of the C5a des Arg cochemotaxin. Homology with vitamin D binding protein (group-specific component globulin). J Clin Invest 82, 360-3.

16.Perez, H. D., Elfman, F., and Lobo, E. (1987).

Removal of human polymorphonuclear leukocyte surface sialic acid inhibits reexpression (or recycling) of formyl peptide receptors. A possible explanation for its effect on formyl peptide-induced polymorphonuclear leukocyte chemotaxis. J Immunol 139, 1978-84.

17.Perez, H. D., Elfman, F., and Marder, S. (1987).

Meclofenamate sodium monohydrate inhibits chemotactic factor-induced human polymorphonuclear leukocyte function.

A possible explanation for its antiinflammatory effect. Arthritis Rheum 30, 1023-31.

18.Perez, H. D., Marder, S., Elfman, F., and Ives, H. E. (1987).

Human neutrophils contain subpopulations of specific granules exhibiting different sensitivities to changes in cytosolic free calcium. Biochim Biophys Res Commun 145, 976-81.

19.Perez, H. D., Elfman, F., Lobo, E., Sklar, L., Chenoweth, D., and Hooper, C. (1986).

A derivative of wheat germ agglutinin specifically inhibits formyl-peptide-induced polymorphonuclear leukocyte chemotaxis by blocking re-expression (or recycling) of receptors. J Immunol 136, 1803-12.

20.Perez, H. D., Elfman, F., Chenoweth, D., and Hooper, C. (1986).

Preparation and characterization of a derivative of wheat germ agglutinin which specifically inhibits polymorphonuclear leukocyte chemotaxis to the synthetic chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine. J Immunol 136, 1813-9.

21.Perez, H. D., Ong, R. R., and Elfman, F. (1985).

Removal or oxidation of surface membrane sialic acid inhibits formyl-peptide-induced polymorphonuclear leukocyte chemotaxis. J Immunol 134, 1902-8.

From Publication #2, Journal of Virology (2007) Vol. 81, 110**-*****:

Cover photograph (Copyright © 2007, American Society for Microbiology. All Rights Reserved.): Confocal image of a spontaneously reactivating neuron in a latently infected mouse trigeminal ganglion. Nuclear staining (blue), neuron-specific staining (red), herpes simplex virus type 1-specific staining (green). (See related article on page 11069.)

Contact this candidate